News

Our Healthcare News

Essex Woodlands Fund IX Acquires Significant Position in AxoGen, Inc.

ALACHUA, Florida—AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has sold 4,861,111 registered shares of its…  

Aug 27 2015

Catalyst Biosciences Completes Merger with Targacept

SOUTH SAN FRANCISCO, California—(GLOBE NEWSWIRE)—Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, today…  

Aug 20 2015

Entellus Medical Announces Collaboration with Fiagon

PLYMOUTH, Minnesota—Entellus Medical, Inc. (“Entellus Medical” or the “Company”) (NASDAQ: ENTL), a medical technology company focused on the design, development and commercialization of products for…  

Aug 10 2015

Corium Prices Follow-On Offering of Common Stock

MENLO PARK, California (GLOBE NEWSWIRE)—Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced…  

Aug 05 2015

Abiomed Announces Q1 FY 2016 Revenue of $73.4 Million, Up 50% Over Prior Year

DANVERS, Massachusetts—Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2016 revenue of $73.4 million, an increase…  

Aug 04 2015

Entellus Medical Announces Positive 24 Month Data from Remodel Trial, Meta-Analysis Across 6 Studies

PLYMOUTH, Minnesota—Entellus Medical, Inc. (NASDAQ: ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in…  

Jul 31 2015

Corium Reports Third Quarter Fiscal 2015 Financial Results

MENLO PARK, California—Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited…  

Jul 29 2015

Corium Announces Positive Topline Results from Phase 2a Study of Transdermal MicroCor PTH

MENLO PARK, California—Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced positive topline…  

Jul 28 2015

Corium Co-Founder Dr. Gary W. Cleary Honored with Controlled Release Society Founders Award

MENLO PARK, California—Corium International, Inc. (NASDAQ:  CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that…  

Jul 27 2015